Belite Bio, Inc (NASDAQ:BLTE) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET

Company Participants

Tom Lin – Chief Executive Officer

Nathan Mata – Chief Scientific Officer

Hao-Yuan Chuang – Chief Financial Officer

Conference Call Participants

Bruce Jackson – The Benchmark Company

Unidentified Company Representative

[Call Starts Abruptly] First Half 2022 Financial Results Conference Call. After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded. Yesterday, Belite Bio issued a news release announcing the company’s financial results for the first half of fiscal 2022. And it’s available within the new section of the company’s IR website at www.investorsbelitebio.com.

Additionally, the presentation has been uploaded to the Event section of the company’s IR website. If participants joining via webcasting, find that the slide presentation is not synchronizing. Please refresh the webpage and make sure to click on the play icon at the bottom left corner. Alternatively, please visit the Event section of our IR website to view the presentation.

I’d like to remind you that the statements we are about to make today may include statements relating to Belite Bio’s business plans and future prospects that are forward-looking statement in the meaning of the Private Securities Litigation Reform Act of 1995. These statements cover many events and matters that are subject to various risks that could cause actual results to differ materially from those expressed or implied in any forward-looking statement we make. I encourage you to review the forward-looking statement section included in our Form 6-K furnished on August 10th for detailed description of the Risk Factors affecting our business that could cause those differences. In addition, any forward-looking statement mentioned above represents our views only as of today. And we do not undertake any obligation to update any forward-looking statement except as required under ethical law.

Representing Belite Bio today, are Dr. Tom Lin, CEO; Dr. Nathan Mata, CSO; and Mr. Hao-Yuan Chuang, CFO. I’d now like to turn the call over to Tom. Tom?

Tom Lin

Thanks, Chris. And thanks everyone for joining this call. I’m Tom Lin, CEO of like Belite Bio, and just like to give a quick background on myself. I’ve trained in Medicine of Surgery and also did my PhD in Neurology where my research focus was on developing treatments for neurodegenerative disease. For most of my career, I’ve led several novel drug developments in multiple therapeutic areas. And prior to founding Belite Bio and Lin Bioscience, I have led to startup companies to IPO.